EUCTR2016-002004-10-FR进行中（未招募）1 期
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient must be above the age of 1 month as of the start date of study treatment.
- •2. Patient must be scheduled to undergo allogeneic (adults or pediatric patients) or autologous HSCT (pediatric patients only) and be at high risk or very high risk of developing VOD.
- •a. High-risk patients must meet both of the following criteria (i and ii):
- •i. Patient must be scheduled to receive myeloablative conditioning, defined as either of the following:
- •a. At least 2 alkylating agents (e.g., cyclophosphamide, busulfan, melphalan); the investigator must document in the medical chart that the conditioning regimen is considered to be myeloablative
- •b. TBI (single dose of =5 Gy, or =8 Gy fractionated dose) and at least 1 alkylating agent, and
- •ii. Patient must meet at least 1 of the following criteria (a or b):
- •a. Have at least 1 hepatic-related risk factor, as defined by the EBMT position statement at screening:
- •Transaminase level >2.5 times the upper limit of normal (ULN)
- •Serum total bilirubin level >1.5 times the ULN
- •Cirrhosis (with biopsy evidence)
- •Hepatic fibrosis (by histology)
- •Known history of active viral hepatitis within 1 year before the start of study treatment, as indicated by an available positive test result for any of the following: hepatitis A virus (HAV) immunoglobulin M (IgM) antibody; hepatitis B virus (HBV) core IgM antibody; HBV surface antigen; hepatitis C virus (HCV) antibody with HCV polymerase chain reaction (PCR) test (or HCV PCR alone)
- •Any prior hepatic irradiation, including abdominal irradiation covering the hepatic area
- •Documented diagnosis of iron overload (serum ferritin >2000 ng/mL)
- •b. Has advanced-stage neuroblastoma requiring myeloablative conditioning
- •b. Very high-risk patients must meet one of the following criteria:
- •i. Osteopetrosis and undergoing myeloablative conditioning
- •ii. Primary HLH, Griscelli II Chediak-Higashi syndrome, Hermansky-Pudiak II, X-linked lymphoproliferative disorders, X-linked severe combined immunodeficiency, X-linked hypogammaglobulinemia, or familial HLH 1-5 and undergoing myeloablative conditioning
- •iii.Prior treatment with an ozogamicin-containing monoclonal antibody using the minimum dose and schedule, according to the patient prescribong information;
- •iv.Class III, high-risk thalassemia (i.e., patients who are =7 years old and have a liver size =5 cm at the time of screening
- •3. Female patients of childbearing potential who are sexually active must agree to use a medically acceptable method of contraception throughout the entire study period and for 4 weeks after the last dose of study drug; male patients with female partners of childbearing potential must agree to use a medically acceptable method of contraception for 6 months after the last dose of study drug. Medically acceptable methods of
- •contraception that may be used by the patient and/or partner include abstinence, birth control pills, patches, vaginal ring, diaphragm and spermicide, condom and vaginal spermicide, surgical sterilization, vasectomy (>6 months before Study Day 1), and progestin implant or injection. Post-menopausal women (i.e., women with >2 years of amenorrhea) do not need to use contraception.
- •4. Patient and/or the legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age
排除标准
- •1. Patient has hemodynamic instability within 24 hours before the start of study treatment.
- •2. Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment, defined as either of the following:
- •a. hemorrhage requiring >15 cc/kg of packed red blood cells (e.g., pediatric patient weighing 20 kg and requiring 300 cc packed red blood cells/24 hours, or an adult weighing >70 kg and requiring 3 units of packed red blood cells/24 hours) to replace blood loss, or
- •b. bleeding from a site which, in the investigator’s opinion, constitutes a potential life-threatening source (e.g., pulmonary hemorrhage or central nervous system bleeding), irrespective of amount of blood loss
- •3. Patient used any medication that increases the risk of bleeding within 24 hours before the start of study treatment, including, but not limited to, systemic heparin, low molecular weight heparin, heparin analogs, alteplase, streptokinase, urokinase, ATIII, and oral anticoagulants including warfarin, and other agents that increase the risk of bleeding.
- •Note: Heparin used to keep catheters open will be allowed (up to a maximum of 100 U/kg/day).
- •4. Patient is using or plans to use an investigational agent for the prevention or treatment of VOD.
- •5. Patient, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- •6. Patient has a psychiatric illness that would prevent the patient or legal guardian or representative from giving informed consent and/or assent.
- •7. Patient has a serious active disease or co-morbid medical condition, as judged by the investigator, which would interfere with the conduct of this study.
- •8. Patient is pregnant or lactating and does not agree to stop breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to investigate the efficacy and safety of Defibrotide compared with Best Supportive Care in the prevention of Hepatic Veno-Occlusive Disease in adult and pediatric patients Undergoing Hematopoietic Stem Cell Transplant.Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell TransplantMedDRA version: 20.0Level: LLTClassification code 10047207Term: Veno-occlusive liver damageSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0Level: LLTClassification code 10047217Term: Venoocclusive syndrome of the liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0Level: PTClassification code 10047216Term: Venoocclusive liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002004-10-DEJazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A clinical study to investigate the efficacy and safety of Defibrotide compared with Best Supportive Care in the prevention of Hepatic Veno-Occlusive Disease in adult and pediatric patients Undergoing Hematopoietic Stem Cell Transplant.Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell TransplantMedDRA version: 20.0Level: LLTClassification code 10047207Term: Veno-occlusive liver damageSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0Level: LLTClassification code 10047217Term: Venoocclusive syndrome of the liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0Level: PTClassification code 10047216Term: Venoocclusive liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002004-10-GBJazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A clinical study to investigate the efficacy and safety of Defibrotide compared with Best Supportive Care in the prevention of Hepatic Veno-Occlusive Disease in adult and pediatric patients Undergoing Hematopoietic Stem Cell Transplant.Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell TransplantMedDRA version: 19.0Level: LLTClassification code 10047207Term: Veno-occlusive liver damageSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 19.0Level: LLTClassification code 10047217Term: Venoocclusive syndrome of the liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 19.0Level: PTClassification code 10047216Term: Venoocclusive liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002004-10-ESJazz Pharmaceuticals, Inc.372
进行中（未招募）
1 期
A clinical study to investigate the efficacy and safety of Defibrotide compared with Best Supportive Care in the prevention of Hepatic Veno-Occlusive Disease in adult and pediatric patients Undergoing Hematopoietic Stem Cell Transplant.Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell TransplantMedDRA version: 20.0Level: LLTClassification code 10047207Term: Veno-occlusive liver damageSystem Organ Class: 100000022943MedDRA version: 20.0Level: LLTClassification code 10047217Term: Venoocclusive syndrome of the liverSystem Organ Class: 100000022943MedDRA version: 20.0Level: PTClassification code 10047216Term: Venoocclusive liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002004-10-BEJazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A clinical study to investigate the efficacy and safety of Defibrotide compared with Best Supportive Care in the prevention of Hepatic Veno-Occlusive Disease in adult and pediatric patients Undergoing Hematopoietic Stem Cell Transplant.Prevention of Hepatic Veno-Occlusive Disease following Hematopoietic Stem Cell TransplantMedDRA version: 19.0Level: LLTClassification code 10047207Term: Veno-occlusive liver damageSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 19.0Level: LLTClassification code 10047217Term: Venoocclusive syndrome of the liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 19.0Level: PTClassification code 10047216Term: Venoocclusive liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002004-10-ITJazz Pharmaceuticals, Inc.400